Taken together, our studies encourage further efforts to uncover and evaluate LOXL1 related drug targets mediating the malignant progression of CRC and provide molecular mechanisms to support a new theoretical basis for the advancement of clinical treatments. The gene discussed is LOXL1; the disease is colorectal carcinoma.